TTK and cancer: Unfortunately, in cancer cells, the resistance to Mps1 inhibitors eventually occurs and this resistance is mostly due to mutations in the conserved ATP binding pocket of the Mps1 kinase domain, which leads to a remarkably attenuation of the therapeutic efficiency of the Mps1 inhibitors (Hiruma et al., 2017; Koch et al., 2016).